This document summarizes the findings of the Makkah Heart Failure Registry (MHFR) which included 993 heart failure patients treated at King Abdullah Medical City between October 2018 and June 2021. The average age was 56.9 years and 75.7% were male. Etiologies included ischemic (43.1%), dilated (35%), and other causes (21.8%). Patients were divided into three groups: Group I (33.1%) received sacubitril and had more severe disease, Group II (59%) received standard medical therapy, and Group III (7.8%) were patients evaluated during Hajj in 2019. The registry provides insights into the demographics, characteristics, treatments, and outcomes of
1. This document describes the case of a 39-year-old man with a history of heart failure readmissions spanning from 2016 to 2020.
2. He initially presented in 2016 with a STEMI and was found to have severe left ventricular dysfunction. He had recurrent hospitalizations for heart failure exacerbations and NSTEMIs.
3. By 2020, he was deemed a candidate for advanced heart failure therapies but was not eligible due to non-compliance with medications and ongoing substance abuse issues.
4. After his last hospitalization in August 2020, he committed to stopping substance abuse and adhering to medical treatment, marking a turning point in his long journey with advanced heart failure.
This document discusses cardio-oncology syndromes, specifically chemotherapy-induced cardiomyopathy (CCMP). It presents a case study of a 36-year-old female with no prior heart issues who was diagnosed with acute myeloid leukemia. After receiving chemotherapy, she developed severe heart failure within 2 weeks and died. CCMP can cause heart failure in 1-5% of cancer survivors treated with anthracyclines and risk increases with higher cumulative doses. This was an acute case of CCMP resulting in advanced heart failure and death in a previously healthy young patient.
This case discusses a 30-year-old female patient who presented with cardiogenic/septic shock and was discovered to have Hodgkin's lymphoma. She had severely reduced left ventricular function (EF 25-30%) and heart failure symptoms. She received chemotherapy without the standard ABVD regimen due to her heart failure. Throughout chemotherapy, her heart failure was closely monitored and managed medically. Serial echocardiograms showed improvement in her cardiac function, with EF returning to normal range after one year. This case demonstrates that chemotherapy can potentially cure or reverse heart failure in rare cases of cardiac involvement by lymphoma.
1) The document discusses emergency heart failure services and alternatives to hospitalization for patients presenting to the emergency department with acute heart failure.
2) It describes how the majority of heart failure admissions and readmissions originate in the emergency department, and that 50% of cases may be safely discharged after observation and treatment.
3) The document proposes establishing an emergency-based heart failure observation unit to treat and risk-stratify patients, with the goal of facilitating safe discharges and avoiding unnecessary hospital admissions for low-risk cases.
This document summarizes the case of a 34-year-old diabetic male who was admitted to the emergency room with an acute myocardial infarction involving the inferior wall and right ventricle. He developed acute heart failure, a ventricular septal rupture, cardiogenic shock, acute cardiogenic renal injury, and cardiogenic hypoxic hepatitis. Despite intensive care treatment, he expired within 27 hours of admission. The document then provides clinical summaries and test results from his hospitalization that demonstrate the development of acute cardiogenic liver injury from his acute heart failure.
1. This document describes the case of a 39-year-old man with a history of heart failure readmissions spanning from 2016 to 2020.
2. He initially presented in 2016 with a STEMI and was found to have severe left ventricular dysfunction. He had recurrent hospitalizations for heart failure exacerbations and NSTEMIs.
3. By 2020, he was deemed a candidate for advanced heart failure therapies but was not eligible due to non-compliance with medications and ongoing substance abuse issues.
4. After his last hospitalization in August 2020, he committed to stopping substance abuse and adhering to medical treatment, marking a turning point in his long journey with advanced heart failure.
This document discusses cardio-oncology syndromes, specifically chemotherapy-induced cardiomyopathy (CCMP). It presents a case study of a 36-year-old female with no prior heart issues who was diagnosed with acute myeloid leukemia. After receiving chemotherapy, she developed severe heart failure within 2 weeks and died. CCMP can cause heart failure in 1-5% of cancer survivors treated with anthracyclines and risk increases with higher cumulative doses. This was an acute case of CCMP resulting in advanced heart failure and death in a previously healthy young patient.
This case discusses a 30-year-old female patient who presented with cardiogenic/septic shock and was discovered to have Hodgkin's lymphoma. She had severely reduced left ventricular function (EF 25-30%) and heart failure symptoms. She received chemotherapy without the standard ABVD regimen due to her heart failure. Throughout chemotherapy, her heart failure was closely monitored and managed medically. Serial echocardiograms showed improvement in her cardiac function, with EF returning to normal range after one year. This case demonstrates that chemotherapy can potentially cure or reverse heart failure in rare cases of cardiac involvement by lymphoma.
1) The document discusses emergency heart failure services and alternatives to hospitalization for patients presenting to the emergency department with acute heart failure.
2) It describes how the majority of heart failure admissions and readmissions originate in the emergency department, and that 50% of cases may be safely discharged after observation and treatment.
3) The document proposes establishing an emergency-based heart failure observation unit to treat and risk-stratify patients, with the goal of facilitating safe discharges and avoiding unnecessary hospital admissions for low-risk cases.
This document summarizes the case of a 34-year-old diabetic male who was admitted to the emergency room with an acute myocardial infarction involving the inferior wall and right ventricle. He developed acute heart failure, a ventricular septal rupture, cardiogenic shock, acute cardiogenic renal injury, and cardiogenic hypoxic hepatitis. Despite intensive care treatment, he expired within 27 hours of admission. The document then provides clinical summaries and test results from his hospitalization that demonstrate the development of acute cardiogenic liver injury from his acute heart failure.
This document discusses guidelines for heart failure patients fasting during Ramadan. It recommends that patients monitor their weight daily and fluid intake, restrict salt and sugar, continue medications, and not omit doses. Those with advanced heart failure should avoid fasting. The document outlines 10 heart failure syndromes that require contacting a physician and provides a daily curriculum for heart failure patients, including understanding their condition and treatment, monitoring symptoms and weight, and being aware of heart failure zones.
This document presents a classification system for heart failure syndromes developed by Asadullah Khan Soomro based on 30 years of experience. It describes 6 categories of heart failure - acute de novo, chronic compensated, acute decompensation of chronic HF, chronic advanced HF, and malignant acute de novo HF. Examples of each category are provided through brief case summaries with relevant clinical information. The classification aims to distinguish between "benign" and "malignant" forms of heart failure and guide appropriate management and prevention of hospital admissions.
New toy in town,non dilated non ischemic HFasadsoomro1960
This document describes the case of a 62-year-old man who presented with de novo heart failure with severe left ventricular systolic dysfunction and normal coronary arteries. He was started on sacubitril/valsartan and showed significant improvements over 15 months, including increased ejection fraction and decreased BNP, without any readmissions. The case demonstrates that reversible etiologies can cause heart failure and ARNI treatment can lead to functional recovery in some cases of non-ischemic cardiomyopathy.
Community Heart Failure Services in Holy Makkah aims to establish a comprehensive heart failure care program through various models of care. The document outlines gaps in care for heart failure patients at the community level, including a lack of education, standardized referral processes, and coordinated long-term management. It proposes a community heart failure clinic model to help address these issues by utilizing family physicians and improving prevention, screening, and management of asymptomatic heart failure patients earlier in the disease process. Establishing such services could help reduce hospital readmissions, emergency department visits, and overall costs by providing more coordinated, evidence-based care across different levels of the healthcare system.
Ischemic hf type 1 v case presentation.june 21asadsoomro1960
This patient, a 50-year-old male smoker and hypertensive, presented with progressive breathlessness and fatigue over 6 months and was admitted for decompensated chronic heart failure. Imaging showed severe left ventricular dysfunction and diffuse three-vessel coronary artery disease. He underwent coronary artery bypass grafting but experienced significant bleeding complications, receiving over 100 units of blood products. His condition deteriorated with multi-organ failure and he expired within 24 hours of CABG.
The document discusses devices used in advanced heart failure syndromes. It provides definitions of heart failure and advanced heart failure. It discusses recommendations for implanting devices like ICDs and CRT to treat heart failure. It describes various mechanical circulatory support devices that can be used as bridges to decision, candidacy, transplantation or as destination therapy. It discusses patient selection criteria for long-term left ventricular assist devices based on INTERMACS profiles and guidelines.
Ischemic heart failure benign or malignantasadsoomro1960
This document discusses a case of a 50-year-old male patient who presented with progressive breathlessness and fatigue. Evaluation showed severe left ventricular systolic dysfunction. Coronary angiography revealed severe diffuse 3-vessel coronary artery disease. The patient underwent high-risk coronary artery bypass grafting but developed hemorrhagic shock post-operatively and expired despite maximum support including ECMO. The case illustrates Type IV ischemic heart failure, where coronary artery disease is the underlying cause of heart failure but was not detected initially due to non-invasive testing.
This document describes a case of statin-induced rhabdomyolysis in a 52-year-old man. The patient presented with chest pain and was found to have coronary artery disease, for which he underwent PCI. He developed complications including renal failure and was diagnosed with rhabdomyolysis after being on atorvastatin 40mg daily for two weeks. Key lab results included markedly elevated CPK and worsening renal function. After stopping the statin, his condition gradually improved but he was left with left-sided hemiplegia. The document discusses causes and presentation of rhabdomyolysis, and notes statins are a common cause of this potentially life-threatening condition.
This document provides guidelines for the management of ST-elevation myocardial infarction (STEMI) from the 2017 European Society of Cardiology. It outlines recommendations for emergency care, reperfusion strategies including primary percutaneous coronary intervention (PCI) and pharmacoinvasive strategies. It also discusses adjunctive therapies, imaging, long-term drug therapies, and new concepts in the 2017 version compared to 2012, including the management of myocardial infarction with non-obstructive coronary arteries (MINOCA). The guidelines emphasize short timelines for reperfusion and emphasize radial access and new generation drug-eluting stents for primary PCI.
Hurdles and new players in the management of chronic heart failure with reduc...Dhritisdiary
Watch the slideshow for a better understanding: https://youtu.be/CsXvS1hA330
1. Learn the standard therapy in HFrEF
2. Learn its challenges
3. Learn the new drugs for HFrEF.
Prediction and Prevention in Sudden Cardiac DeathApollo Hospitals
This document discusses prediction and prevention of sudden cardiac death (SCD). It begins by stating that SCD is the most common cause of death worldwide, accounting for over 50% of cardiovascular deaths. The document then discusses various risk factors for SCD, including left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, electrocardiogram abnormalities like prolonged QRS duration and QT interval. It states that while LVEF <30-35% is the most consistent predictor of cardiac mortality, current risk stratification techniques lack sufficient predictive value to identify high-risk individuals. The document emphasizes the need for improved prediction and prevention strategies given the high mortality from SCD.
In this ppt, I am going to discuss the role of ICD in the patient with Non-ischemic cardiomyopathy. I am going to discuss all the major trials done in the patient with non-ischemic cardiomyopathy.
This document summarizes a symposium on heart failure held on January 23rd, 2013 sponsored by Servier Laboratories. The full-day programme consisted of two sessions with multiple speakers covering topics such as the epidemiology, diagnosis, and management of acute and chronic heart failure. New diagnostic tools and treatments discussed include biomarkers like galectin-3 and BNP, cardiac imaging modalities, device therapies, and novel drugs in development. Prognostic factors and approaches to integrated end-of-life care in heart failure were also addressed.
The document summarizes key information about acute heart failure, including epidemiology, pathophysiology, treatment approaches, and trial data. It describes the ASCEND-HF trial which investigated the effects of nesiritide vs placebo on outcomes in over 7,000 patients hospitalized for acute decompensated heart failure. The trial found no significant differences between nesiritide and placebo for its co-primary endpoints of 30-day mortality or heart failure rehospitalization and dyspnea relief at 6 and 24 hours.
Low dose dopamine increases GFR and RBF. The DAD-HF trial investigated 60 patients randomized to low dose furosemide (continuous infusion 0.5 mg/kg/day) with or without low dose dopamine (2 μg/kg/min). Dopamine preserved renal function compared to furosemide alone in patients with acute decompensated heart failure. There were no significant differences found in a trial comparing high vs low dose furosemide or bolus vs continuous infusion on renal function or symptoms. Novel agents targeting fluid overload, renal function, contractility, and vasomotion may provide new therapeutic options for acute heart failure.
This document discusses acute decompensated heart failure (ADHF), which refers to new or worsening signs and symptoms of heart failure requiring medical care or hospitalization. ADHF accounts for over 50% of heart failure costs in the US. It has a high mortality and readmission rate. The document outlines common causes and presentations of ADHF and emphasizes the importance of a thorough clinical evaluation to diagnose ADHF and distinguish it from other potential causes of symptoms like shortness of breath. It describes assessing signs of congestion and hypoperfusion to classify patients and guide initial treatment.
This document discusses catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition characterized by adrenergically mediated polymorphic ventricular arrhythmias without structural heart disease. It has a prevalence of 1 in 10,000 and mortality of up to 50% before age 20 if untreated. The gold standard for diagnosis is exercise stress testing showing exercise-induced bidirectional or polymorphic ventricular tachycardia. Treatment involves lifestyle changes, beta-blockers, flecainide, and an ICD for those with cardiac arrest or recurrent arrhythmias despite medical therapy. Genetic testing identifies mutations in RYR2 or CASQ2 genes in the majority of cases.
This document summarizes key information about chronic kidney disease (CKD) and cardiovascular disease (CVD). It notes that patients with CKD should be considered at the highest risk for CVD. Lower estimated glomerular filtration rate (eGFR) is associated with higher risks of coronary disease and CVD mortality. The risks of all-cause mortality are significantly higher across all levels of eGFR and proteinuria for patients with early diabetic kidney disease compared to those without. Heart failure hospitalization risk increases as kidney function declines. The development of macroalbuminuria in diabetes patients heralds a rapid decline in glomerular filtration rate. Timely protection and maintenance of kidney function can reduce CVD risks.
Epidemiology of Hepatocellular Carcinoma (HCC) In Tertiary Level Hospitals in...JohnJulie1
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide including Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important etiological factors for developing chronic liver disease (CLD) and HCC.
Epidemiology of Hepatocellular Carcinoma (HCC) In Tertiary Level Hospitals in...JapaneseJournalofGas
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide including Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important etiological factors for developing chronic liver disease (CLD) and HCC.
Managing Heart Failure in Patients on Dialysismagdyelmasry3
•
Heart failure and end-stage kidney disease (ESKD) commonly coexist; 1 comorbidity worsens the prognosis of the other.
•
Although patients with ESKD compose an extremely high-risk population, they have been excluded from landmark clinical trials in heart failure, and there is, thus, a paucity of data regarding the management of heart failure in patients on dialysis.
•
Trial-level evidence is warranted in the future to endorse the efficacy and safety of therapeutic interventions in patients with heart failure and on dialysis. Collaborations between cardiologists and nephrologists are needed to devise an optimal treatment strategy for these patients.
This document discusses guidelines for heart failure patients fasting during Ramadan. It recommends that patients monitor their weight daily and fluid intake, restrict salt and sugar, continue medications, and not omit doses. Those with advanced heart failure should avoid fasting. The document outlines 10 heart failure syndromes that require contacting a physician and provides a daily curriculum for heart failure patients, including understanding their condition and treatment, monitoring symptoms and weight, and being aware of heart failure zones.
This document presents a classification system for heart failure syndromes developed by Asadullah Khan Soomro based on 30 years of experience. It describes 6 categories of heart failure - acute de novo, chronic compensated, acute decompensation of chronic HF, chronic advanced HF, and malignant acute de novo HF. Examples of each category are provided through brief case summaries with relevant clinical information. The classification aims to distinguish between "benign" and "malignant" forms of heart failure and guide appropriate management and prevention of hospital admissions.
New toy in town,non dilated non ischemic HFasadsoomro1960
This document describes the case of a 62-year-old man who presented with de novo heart failure with severe left ventricular systolic dysfunction and normal coronary arteries. He was started on sacubitril/valsartan and showed significant improvements over 15 months, including increased ejection fraction and decreased BNP, without any readmissions. The case demonstrates that reversible etiologies can cause heart failure and ARNI treatment can lead to functional recovery in some cases of non-ischemic cardiomyopathy.
Community Heart Failure Services in Holy Makkah aims to establish a comprehensive heart failure care program through various models of care. The document outlines gaps in care for heart failure patients at the community level, including a lack of education, standardized referral processes, and coordinated long-term management. It proposes a community heart failure clinic model to help address these issues by utilizing family physicians and improving prevention, screening, and management of asymptomatic heart failure patients earlier in the disease process. Establishing such services could help reduce hospital readmissions, emergency department visits, and overall costs by providing more coordinated, evidence-based care across different levels of the healthcare system.
Ischemic hf type 1 v case presentation.june 21asadsoomro1960
This patient, a 50-year-old male smoker and hypertensive, presented with progressive breathlessness and fatigue over 6 months and was admitted for decompensated chronic heart failure. Imaging showed severe left ventricular dysfunction and diffuse three-vessel coronary artery disease. He underwent coronary artery bypass grafting but experienced significant bleeding complications, receiving over 100 units of blood products. His condition deteriorated with multi-organ failure and he expired within 24 hours of CABG.
The document discusses devices used in advanced heart failure syndromes. It provides definitions of heart failure and advanced heart failure. It discusses recommendations for implanting devices like ICDs and CRT to treat heart failure. It describes various mechanical circulatory support devices that can be used as bridges to decision, candidacy, transplantation or as destination therapy. It discusses patient selection criteria for long-term left ventricular assist devices based on INTERMACS profiles and guidelines.
Ischemic heart failure benign or malignantasadsoomro1960
This document discusses a case of a 50-year-old male patient who presented with progressive breathlessness and fatigue. Evaluation showed severe left ventricular systolic dysfunction. Coronary angiography revealed severe diffuse 3-vessel coronary artery disease. The patient underwent high-risk coronary artery bypass grafting but developed hemorrhagic shock post-operatively and expired despite maximum support including ECMO. The case illustrates Type IV ischemic heart failure, where coronary artery disease is the underlying cause of heart failure but was not detected initially due to non-invasive testing.
This document describes a case of statin-induced rhabdomyolysis in a 52-year-old man. The patient presented with chest pain and was found to have coronary artery disease, for which he underwent PCI. He developed complications including renal failure and was diagnosed with rhabdomyolysis after being on atorvastatin 40mg daily for two weeks. Key lab results included markedly elevated CPK and worsening renal function. After stopping the statin, his condition gradually improved but he was left with left-sided hemiplegia. The document discusses causes and presentation of rhabdomyolysis, and notes statins are a common cause of this potentially life-threatening condition.
This document provides guidelines for the management of ST-elevation myocardial infarction (STEMI) from the 2017 European Society of Cardiology. It outlines recommendations for emergency care, reperfusion strategies including primary percutaneous coronary intervention (PCI) and pharmacoinvasive strategies. It also discusses adjunctive therapies, imaging, long-term drug therapies, and new concepts in the 2017 version compared to 2012, including the management of myocardial infarction with non-obstructive coronary arteries (MINOCA). The guidelines emphasize short timelines for reperfusion and emphasize radial access and new generation drug-eluting stents for primary PCI.
Hurdles and new players in the management of chronic heart failure with reduc...Dhritisdiary
Watch the slideshow for a better understanding: https://youtu.be/CsXvS1hA330
1. Learn the standard therapy in HFrEF
2. Learn its challenges
3. Learn the new drugs for HFrEF.
Prediction and Prevention in Sudden Cardiac DeathApollo Hospitals
This document discusses prediction and prevention of sudden cardiac death (SCD). It begins by stating that SCD is the most common cause of death worldwide, accounting for over 50% of cardiovascular deaths. The document then discusses various risk factors for SCD, including left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, electrocardiogram abnormalities like prolonged QRS duration and QT interval. It states that while LVEF <30-35% is the most consistent predictor of cardiac mortality, current risk stratification techniques lack sufficient predictive value to identify high-risk individuals. The document emphasizes the need for improved prediction and prevention strategies given the high mortality from SCD.
In this ppt, I am going to discuss the role of ICD in the patient with Non-ischemic cardiomyopathy. I am going to discuss all the major trials done in the patient with non-ischemic cardiomyopathy.
This document summarizes a symposium on heart failure held on January 23rd, 2013 sponsored by Servier Laboratories. The full-day programme consisted of two sessions with multiple speakers covering topics such as the epidemiology, diagnosis, and management of acute and chronic heart failure. New diagnostic tools and treatments discussed include biomarkers like galectin-3 and BNP, cardiac imaging modalities, device therapies, and novel drugs in development. Prognostic factors and approaches to integrated end-of-life care in heart failure were also addressed.
The document summarizes key information about acute heart failure, including epidemiology, pathophysiology, treatment approaches, and trial data. It describes the ASCEND-HF trial which investigated the effects of nesiritide vs placebo on outcomes in over 7,000 patients hospitalized for acute decompensated heart failure. The trial found no significant differences between nesiritide and placebo for its co-primary endpoints of 30-day mortality or heart failure rehospitalization and dyspnea relief at 6 and 24 hours.
Low dose dopamine increases GFR and RBF. The DAD-HF trial investigated 60 patients randomized to low dose furosemide (continuous infusion 0.5 mg/kg/day) with or without low dose dopamine (2 μg/kg/min). Dopamine preserved renal function compared to furosemide alone in patients with acute decompensated heart failure. There were no significant differences found in a trial comparing high vs low dose furosemide or bolus vs continuous infusion on renal function or symptoms. Novel agents targeting fluid overload, renal function, contractility, and vasomotion may provide new therapeutic options for acute heart failure.
This document discusses acute decompensated heart failure (ADHF), which refers to new or worsening signs and symptoms of heart failure requiring medical care or hospitalization. ADHF accounts for over 50% of heart failure costs in the US. It has a high mortality and readmission rate. The document outlines common causes and presentations of ADHF and emphasizes the importance of a thorough clinical evaluation to diagnose ADHF and distinguish it from other potential causes of symptoms like shortness of breath. It describes assessing signs of congestion and hypoperfusion to classify patients and guide initial treatment.
This document discusses catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition characterized by adrenergically mediated polymorphic ventricular arrhythmias without structural heart disease. It has a prevalence of 1 in 10,000 and mortality of up to 50% before age 20 if untreated. The gold standard for diagnosis is exercise stress testing showing exercise-induced bidirectional or polymorphic ventricular tachycardia. Treatment involves lifestyle changes, beta-blockers, flecainide, and an ICD for those with cardiac arrest or recurrent arrhythmias despite medical therapy. Genetic testing identifies mutations in RYR2 or CASQ2 genes in the majority of cases.
This document summarizes key information about chronic kidney disease (CKD) and cardiovascular disease (CVD). It notes that patients with CKD should be considered at the highest risk for CVD. Lower estimated glomerular filtration rate (eGFR) is associated with higher risks of coronary disease and CVD mortality. The risks of all-cause mortality are significantly higher across all levels of eGFR and proteinuria for patients with early diabetic kidney disease compared to those without. Heart failure hospitalization risk increases as kidney function declines. The development of macroalbuminuria in diabetes patients heralds a rapid decline in glomerular filtration rate. Timely protection and maintenance of kidney function can reduce CVD risks.
Epidemiology of Hepatocellular Carcinoma (HCC) In Tertiary Level Hospitals in...JohnJulie1
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide including Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important etiological factors for developing chronic liver disease (CLD) and HCC.
Epidemiology of Hepatocellular Carcinoma (HCC) In Tertiary Level Hospitals in...JapaneseJournalofGas
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide including Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important etiological factors for developing chronic liver disease (CLD) and HCC.
Managing Heart Failure in Patients on Dialysismagdyelmasry3
•
Heart failure and end-stage kidney disease (ESKD) commonly coexist; 1 comorbidity worsens the prognosis of the other.
•
Although patients with ESKD compose an extremely high-risk population, they have been excluded from landmark clinical trials in heart failure, and there is, thus, a paucity of data regarding the management of heart failure in patients on dialysis.
•
Trial-level evidence is warranted in the future to endorse the efficacy and safety of therapeutic interventions in patients with heart failure and on dialysis. Collaborations between cardiologists and nephrologists are needed to devise an optimal treatment strategy for these patients.
- The document describes a study of 800 patients presenting with acute coronary syndrome (ACS) at a tertiary care hospital in Pakistan.
- The mean age was 55.58 years and most patients were male. The most common risk factors were hypertension (48%) and smoking (33.75%).
- Angiography found that single vessel coronary artery disease was most common (20.38%), followed by double vessel (30%) and triple vessel (27.5%). Nearly a quarter (22.25%) had normal coronary vessels.
- The most common treatment was percutaneous coronary intervention (PCI) in 43.75% of patients, while 16.13% were recommended for coronary artery bypass grafting (CAB
ueda2012 glycemic control cvd debate f-d.khalifaueda2015
- While observational studies had previously suggested tighter glycemic control could reduce cardiovascular risk, these randomized trials did not find evidence of cardiovascular benefit when tightly controlling glucose levels, indicating the risks of hypoglycemia outweigh any potential benefits.
Coronary heart disease is best addressed by a comprehensive approach aimed at halting atherosclerotic disease and reducing the risk of thrombosis. Unfortunately, our success in optimal risk factor modification in patients with stable CHD remains poor: only 41% of patients achieved all basic goals in the recent ISCHEMIA trial, with success rates likely even lower outside the rigorous clinical trial context. A greater focus on achieving prevention goals in patients with CHD will have a substantial impact on patient outcome and rates of hospitalization and more resources and incentives should be allocated for improved secondary prevention.
The ISCHEMIA trial suggests that even selected, high-risk patients with extensive ischemic burden do not benefit from revascularization barring unacceptable angina despite OMT. As ISCHEMIA excluded patients with unacceptable angina, advanced heart failure, and those with unprotected left main disease, our evaluation may be geared to identify such patients for consideration of revascularization alongside an initial strategy of OMT.
Atherosclerosis is a systemic disease of the arterial circulation, with focal areas of more severe manifestation. From an imaging standpoint, the paradigm of ischemia testing may have come to an end. Recent evidence from COURAGE, PROMISE, SCOT-HEART, and ISCHEMIA has demonstrated that functional testing for inducible myocardial ischemia is inferior to anatomic assessment for risk stratifying and managing patients with suspected or known CHD. Consistent with a large body of evidence, risk from CHD is mediated by the extent of atherosclerotic disease burden and not by the extent of inducible ischemia. Given that 55% of patients had nonobstructive CHD by CT in PROMISE, which was associated with 77% of cardiovascular deaths and myocardial infarctions at follow-up, there is immense opportunity to impact the disease at an earlier stage in a very large population of patients with occult CHD.
Summary of Hajj Book on cardiovascular Problems & Hajj.asadsoomro1960
Dr. Asadullah Khan Soomro has over 30 years of experience in heart failure, beginning his training in the UK in 1989-1990 before returning to Pakistan. He established one of the first heart failure clinics in Pakistan in 1993 and has since worked to develop heart failure programs in Saudi Arabia. This includes establishing the first heart failure clinic at Prince Sultan Cardiac Center in 2007 and helping the center achieve accreditation as a Clinical Care Program for heart failure. He later helped establish heart failure services at King Abdullah Medical City in Makkah from 2018-2022. Over this time he has registered over 1,000 heart failure patients and pioneered the use of novel heart failure drugs in the region.
Long term outcomes in patients with h fr-ef treated with cabg vs pciRamachandra Barik
RESULTS A total of 12 113 patients (mean [SD] age, 64.8 (11.0) years for the PCI group and 65.6[9.7] years for the CABG group; 5084 (72.5%) male for the PCI group and 4229 (82.9%) malefor the PCI group) were propensity score matched on 30 baseline characteristics: 2397 patients undergoing PCI and 2397 patients undergoing CABG. The median follow-up was 5.2
years (interquartile range, 5.0-5.3). Patients who received PCI had significantly higher rates of
mortality (hazard ratio [HR], 1.6; 95% CI, 1.3-1.7), death from cardiovascular disease (HR 1.4,95% CI, 1.1-1.6), MACE (HR, 2.0; 95% CI, 1.9-2.2), subsequent revascularization (HR, 3.7; 95%
CI, 3.2-4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6-3.8) and heart failure (HR, 1.5;95% CI, 1.3-1.6) compared with matched patients who underwent CABG.
This document provides a scientific statement on the contemporary diagnosis and management of rheumatic heart disease from the American Heart Association. It finds that rheumatic heart disease continues to significantly burden poor and marginalized populations globally, with most affected patients presenting with heart failure in endemic regions. The statement examines current recommendations and identifies gaps in diagnosis and treatment worldwide in order to inform strategies for reducing disease burden. Echocardiography screening shows promise for earlier identification of patients when prophylaxis may be more effective, but further research is still needed. Population registries, benzathine penicillin injections, heart failure management, endocarditis prevention, and valve surgery/replacement are all discussed as important therapeutic approaches, but challenges remain, particularly in
Evaluation of Cardiac Complications in Pateint Undergoing COVID 19 Treatment:...DrHeena tiwari
This study evaluated cardiac complications in 45 COVID-19 patients admitted to the intensive care unit. Electrocardiography and Holter monitoring found various arrhythmias in patients, with atrial fibrillation, premature ventricular contraction, and tachycardia being most common. The mortality rate of arrhythmias in COVID-19 patients was 17.77%. Although arrhythmias are not very frequent in COVID-19, they can be fatal and have a high mortality rate. Early detection of arrhythmias can help prevent deaths.
This document summarizes the cardiovascular risk of patients with type 2 diabetes mellitus (T2DM) in India and the potential benefits of SGLT2 inhibitor treatment. It finds that:
1) The majority of Indian outpatients with T2DM have at least moderate cardiovascular disease (CVD) risk, and over 35% have known CVD.
2) T2DM confers 2-4 times greater CVD risk regardless of duration, and risk increases with longer duration.
3) Empagliflozin treatment consistently reduces the risk of cardiovascular death and heart failure hospitalizations in clinical trials of patients with T2DM and atherosclerotic CVD.
4) Empagliflozin may provide additional benefits
Coronary Revascularization in Chronic Kidney Disease Patient.pptxDr. Nayan Ray
Chronic kidney disease (CKD) is an independent risk factor for the development of coronary artery disease, and for more severe coronary heart disease (CHD).
CKD is also associated with adverse outcomes in those with existing cardiovascular disease.
This includes increased mortality after an acute coronary syndrome, after percutaneous coronary intervention (PCI) with or without stenting, and after coronary artery bypass. In addition, patients with CKD are more likely to present with atypical symptoms, which may delay diagnosis and adversely affect outcomes.
DIVERTICULAR DISEASES-ASSOCIATED COLECTOMY IN URBAN AFRICAN AMERICAN PATIENTS: A HOSPITAL BASED STUDY. S. Ghavimi, H. Brim, H, Ashkorab. Dept. of Medicine and Cancer Center, Howard University Hospital, Washington, DC.
Diverticular Diseases (DD) are generally benign and are primarily detected as incidental finding during routine colonoscopies. However, in certain cases, DD might lead to colectomy.
Method: We reviewed 2400 patients’ files that correspond to DD patients seen at Howard University Hospital from1996 to 2014. Clinical and pathological features of patients that ended up having colectomy were analyzed in details.
Results: Among the 2400 DD cases, there were 59.8% females and 40.2%males, of which 2020 (60%) had diverticulosis while 380 (40%) had diverticulitis. Colectomy was performed in 174 (7.3%) patients of which 112 (64%) had Diverticulosis and 62 (36%) had Diverticulitis. Of the Diverticulosis/Colectomy patients, 92 (82%) had hemorrhage, of which 34 (40%) had massive GI bleeding. Of the Diverticulitis/Colectomy patients, only 14 (23%) had hemorrhage. From the 48 patients without hemorrhage, 31(65%) had recurrent diverticulitis and the remaining 17 (35%) fit the Hinechey Criteria with 5 cases at stage 1, 3 at stage 2, 5 at stage 3 and 4 at stage 4.
Conclusion: This study reveals that a sizable portion of African Americans with DD undergo colectomy due primarily to hemorrhage in diverticulosis patients. Such patients will benefit from periodical FOBT to catch potential massive bleeding at early stages. This applies to diverticulitis patients as well, however, in these patients, recurrence of diverticulitis is the primary indicator for colectomy.
This document provides information about the 7th International Conference on Biotechnology, Bioinformatics, Bio Medical Sciences and Stem Cell Applications that was held from November 11-12, 2016 at the Nanyang Technological University in Singapore. It lists the conference venue and contact information. It also provides details about the plenary speaker, Yoshiko Yamaguchi, and includes the abstract of a study presented on hypertension in Sohag City, Egypt.
The document summarizes epidemiological data on cardiovascular disease (CVD) risk factors in Saudi Arabia. It finds that CVD is the main cause of mortality, accounting for 30% of deaths. The main modifiable risk factors for CVD in Saudi Arabia are hypertension, diabetes, dyslipidemia, cigarette smoking, obesity, and lack of physical activity. The document then provides data on the prevalence of these risk factors in Saudi Arabia based on various epidemiological studies.
Study of Congenital Heart Diseases in Pediatric Patientinventionjournals
Introduction: Congenital heart disease is important cause of morbidity and mortality in pediatric practice. Objectives: - 1) To establish the diagnosis and find out incidence of CHD in various age group. 2) To study various mode of presentation of various CHDs. 3) To study morbidity and mortality in various CHDs in children. Methodology:- Total 60 cases of congenital heart diseases coming to K.T. Children hospital, Rajkot from July 2016 to November 2016 were studied. Informed consent and detailed history was taken followed by thorough clinical examination as per Performa attached. Echocardiography of all patients was done. School health cards were prepared for the patients having abnormal echocardiography and referred to higher centre for cardiologist opinion. Conclusion:- Correct diagnosis can be made with help of thorough history and clinical examination especially in acyanotic congenital heart diseases. Early diagnosis and timely referral of patient can greatly improve outcome of patients with CHDs.
The ISCHEMIA-EXTEND trial followed patients from the original ISCHEMIA trial for a median of 5.7 years to compare long-term outcomes of an initial invasive vs conservative strategy for chronic coronary disease. The study found no difference in all-cause mortality between the two strategies. However, the invasive strategy was associated with a lower risk of cardiovascular mortality but a higher risk of non-cardiovascular mortality. Overall the findings provide longer-term evidence for patients and physicians when deciding between invasive or conservative management for chronic coronary disease.
Its leftover homework of our physician scientist & health care providers for the last 75 years indeed. Contemporary challenges are numerous , but there is a will there is a way ,today or tomorrow some body some where has to start .
Currently heart failure is being treated by every physician ,any where from community to academic institution ,and is based on old system of payment ( FFP ) fee for service ,we need to switch from FFS to Value based payment ( VBP ) .
ZA Bhutto HF Program &networkpart III.pptxasadsoomro1960
This document outlines plans for establishing a multidisciplinary heart failure program and network in Sindh, Pakistan. It is dedicated to Shaheed Zulfiqar Ali Bhutto. The program will improve heart failure services through a coordinated team approach involving cardiologists, nurses, pharmacists, dietitians and other specialists. Referral criteria and pathways between hospitals are discussed to ensure patients receive the right level of care, including early referral for advanced therapies. Operational considerations include determining the patient population served, clinic staffing, appointment structures and developing relationships with other departments.
ZA Bhutto HF program & network Part II.pptxasadsoomro1960
This document discusses building a multidisciplinary heart failure program and network in Sindh, Pakistan. It provides an overview of heart failure, the need for such a program due to rising rates of heart failure and gaps in care. It outlines steps to build the program, including establishing multidisciplinary heart failure clinics at different levels (grades) of care. It also discusses considerations for patient care, including evaluating new patients, follow up visits, medical therapy, device therapy, and goals of the program.
ZA Bhutto HF program & clinic network Part I.pptxasadsoomro1960
This document describes the author's 33-year journey working in heart failure in Pakistan, Saudi Arabia, and the UK. It provides details of his work establishing some of the first heart failure clinics and programs in the regions. It also summarizes a heart failure registry of 993 patients from King Abdullah Medical City in Saudi Arabia between 2018-2021. The registry found the average age was 56.9 years, 75.7% were male, 38.7-64.9% had an ischemic etiology, and 52.1% of those on sacubitril were titrated to the target dose.
Cancer & Heart. Cardio oncological syndromesasadsoomro1960
This document discusses the relationship between cancer and heart failure. It notes that chemotherapy can cure cancer but often causes heart failure as a side effect. Both cancer and heart disease are leading causes of death worldwide. Cancer treatments have increased survival rates but also increase the risk of chronic heart conditions like chemotherapy-related cardiomyopathy. The document advocates for increased screening, prevention, and management of cardiovascular toxicity from cancer treatments to help cancer patients live longer and healthier lives after treatment.
2 Tiger & one elephant HF .when Heart Kills liver.pptxasadsoomro1960
This document summarizes the case of a 34-year-old diabetic male who was admitted to the emergency room with an acute myocardial infarction and right ventricular extension. He developed acute heart failure, a ventricular septal rupture, cardiogenic shock, acute cardiogenic renal injury, and cardiogenic hypoxic hepatitis. Despite intensive care treatment, he expired within 27 hours of admission. The document then provides clinical summaries and test results from his hospital stay, highlighting the progression of liver dysfunction caused by the acute heart failure.
New Toy in Town,Non Dilated Non Ischemic HF.pptxasadsoomro1960
This document describes the case of a 62-year-old man who presented with de novo heart failure with severe left ventricular systolic dysfunction and normal coronary arteries. He was started on sacubitril/valsartan and showed significant improvements over 15 months, including increased ejection fraction and decreased BNP, with no readmissions. The case highlights the potential for recovery in some cases of idiopathic dilated cardiomyopathy with optimal medical therapy like sacubitril/valsartan. It also discusses the classification and management of different heart failure syndromes.
Advanced Heart Failure syndromes .Benign or malignantasadsoomro1960
Despite advances in medical therapy, advanced heart failure (Stage D) carries a dismal prognosis with high mortality. Options like heart transplantation and left ventricular assist devices have improved outcomes but require specialized management. Prevalence of advanced heart failure ranges from 6-25% according to large registries. Progression from chronic heart failure (Stage C) to advanced heart failure is often complex and difficult to determine, requiring integration of multiple clinical parameters to diagnose. Establishment of advanced heart failure centers is needed but unavailable in many countries like Pakistan.
This document discusses the need for heart failure research, particularly at KAMC in Makkah. It notes that heart failure is a growing epidemic responsible for much healthcare expenditure due to frequent readmissions. While treatments now make it preventable and manageable, local data and research are still needed. The document calls for KAMC to support clinical research in heart failure and encourage physician scientists, which are an endangered group. It proposes training programs to expose medical students and young doctors to research opportunities in order to nurture the next generation of cardiovascular clinical researchers in the Holy Makkah region.
1. The document describes several cases of acute cardiogenic liver injury that occurred in patients presenting with acute ischemic heart failure syndromes.
2. Case examples involved patients who developed liver dysfunction indicated by elevated bilirubin and liver enzymes as well as hypoxic hepatitis secondary to cardiogenic shock and malignant heart failure.
3. Poor outcomes included multi-organ failure and death for patients who could not be stabilized hemodynamically and remained in refractory shock despite intervention and medical management.
15 tips to improve HF services in Pakistan.pptxasadsoomro1960
This document provides 15 tips for healthy heart failure living. It begins by defining heart failure, its stages and classifications. It emphasizes understanding the disease and risk factors. It promotes multidisciplinary care, education and rehabilitation. It provides guidance on medication management, lifestyle changes like diet, exercise and monitoring symptoms. It stresses the importance of seeking medical help if symptoms worsen or new concerning symptoms arise. The overall message is that heart failure patients should work closely with medical providers to manage their condition through treatment adherence and self-care.
Million Heart, ticking time bomb can we predict or preventasadsoomro1960
There are different stages of HF syndromes , stage B HF is grossly neglected by cardiology community ,which is a ticking bomb to prevent symptomatic HF
This document presents a classification system for heart failure syndromes developed by Asadullah Khan Soomro based on 30 years of experience. It describes 6 categories of heart failure - acute de novo, chronic compensated, acute decompensation of chronic HF, chronic advanced HF, and malignant acute de novo HF. Examples of each category are provided through brief case summaries with relevant clinical information. The classification aims to distinguish between "benign" and "malignant" forms of heart failure and guide appropriate management through early diagnosis and treatment.
Healthy Heart failure awareness & selfcare zones .asadsoomro1960
The document provides tips and recommendations for maintaining a healthy heart and lifestyle. It encourages regular exercise, a healthy diet, avoiding tobacco and stress, getting adequate sleep, and maintaining a healthy weight. It also recommends visiting a doctor regularly if you have existing heart conditions like high blood pressure, diabetes, or prior heart surgery or issues. The document emphasizes the importance of taking medications as prescribed and getting medical guidance before making any changes.
Biography Dr Soomro. Altamash General Hospital Karachiasadsoomro1960
Dr. Asadullah Khan Soomro is a heart failure specialist and consultant cardiologist offering consultation services at Altamash General Hospital in Karachi. He has over 32 years of experience in heart failure, having worked in the UK, Pakistan, Saudi Arabia, and the Holy City of Makkah. Dr. Soomro established some of the first heart failure clinics and multidisciplinary programs in the regions he worked, and helped centers achieve accreditation for clinical care of heart failure patients. He is retiring from active practice and invites referrals to utilize his experience helping heart failure patients.
Dr soomros 33 years HF journey ,unique experienceasadsoomro1960
This document provides details about Dr. Asadullah Khan Soomro's 33 year career in heart failure. It summarizes his educational background and training in cardiology in Pakistan and the UK. It then outlines his role in establishing some of the first heart failure clinics and programs in Pakistan, Saudi Arabia, and Saudi Arabia. It describes his accomplishments in developing heart failure registries and networks, as well as achieving accreditation for clinical care programs from JCI. The document highlights Dr. Soomro's leadership and contributions over three decades to advancing the treatment of heart failure in various clinical and academic roles across multiple countries in the region.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Makkah HF registry oct 2021
1. MHFR
Makkah Heart Failure Registry
Patients Demoghraphy and clinical characteristics
32nd Saudi Heart Association Virtual
Conference 7th October 2021
DR Asadullah Soomro, Dr Burai Adlan , Dr Abdullah Ghabashi , Dr Fatima Aboul Enein
Dr Najeeb , Dr Hassan Ali, Dr Nadeem Raja, Dr Nazir, Dr Mini, Dr Zainab, Dr Maha, Dr Jawed ,
Dr Jamal, Dr Ghada, Dr shereen , Dr Muntasir , Dr Leila Alkhalifa ,Ebtihal & Others.
Adult Cardiology department King Abdullah Medical City Holy Makkah.
Email: hssbasadsoomro@gmail.com
2.
3. Introduction
64
million
HF is a global pandemic affecting 64 million patients worldwide
( 1-2% of the global population ). 65 to 70% in stage A & B heart Failure
By 2025 30% of the global population will have heart failure.
Frequent
9 of
10
Progressive
Mostly its incurable syndrome, can be reversible
Patients have symptoms despite treatment .
HF is associated with reduced quality of life .
Mortality
Exceeds Most
Cancers
Deadly ,Complex syndromes
77%
5 year mortality of HF exceeds prostatic
cancer./AIDS. >10% die during De-Novo
hospitalization, decline in survival with
recurrent hospitalization
Economic burden of HF is 108
Million dollars worldwide
( 2017) 92,990 high income
and 15,130 in low income
countries.
About 387 million dollars
/year in KSA
Costly ,especially admission and
readmissions ( 30-50% in 6 months )
4. KAMC History of HF Clinic
Heart Failure clinic at KAMC existed since 2014,
We reactivated non functional HF clinic on Tuesday
2nd October 2018.
Our first out patient HF was registered on 9th october
2018 and was switched to ARNI.
Intradepartmental HF consultation service was started and
first inpatient ( ADCHF ) was registered on 15th October 2018
and was switched to ARNI.
Subsequently we introduced early post discharge heart
failure service ( PDHFC ) in November 2019 and Rapid Access
heart failure service ( RAHFC ) in March 2020.
5. MHFR Background
Heart Failure imposes an enormous financial
burden on health care system.
To initiate HF research & development of HF
specialized ( CCPC ) program,King Abdullah Medical
City (KAMC) appropriately design prospective /
observational short ( 30 days hajj 2019 /long term
33 months out patient and in patient heart failure
registry to collect and analyse data of patients who
were referred to KAMC with heterogeneous heart
failure syndromes.
6. MHFR Methods
The data was collected from patients on
specialized proforma .
It included age, gender, LVEF and
Underlying etiology of 993 consecutive
patients who were evaluated & treated
in KAMC for heart failure during
October 2018 to June 2021.
7. MHFR ( Makkah Heart Failure Registry)
Saudi Heart Association Virtual Conference 7th October 2021
Patients Demoghraphy and clinical characteristics
Over all Average age of = 993
56.9 + _ 13.2 Years
18 To 45 years 46 to 65 years Above 65 years
Group I
330 Patients
On Sacubitril
average age =53.9 yr
Group II
586 Patients
Without Sacubitril
Average Age 57.7 Yrs
Group III ,77 Patients
Hajj 2019 ,Average =63.8 yr
71 11 161 33 46 8
77 32 227 73 120 57
2 3 27 13 18 11
Age Distribution
Men Women Men Women Men Women
196 ( 19.7 % ) 537 ( 54.0% ) 260 ( 26.1% )
Total = 993 Patients
150 46 417 119 185 76
82
109
194
300
54
177
41 31
Men,752/993
( 75.7 % ) Age range 19 to 91
Women, 241/993
(24 .2% ) Age range 24 to 85
8. MHFR Makkah Heart Failure Registry
“Sacubitril& Non Sacubitril Audit “
Men = 702
( 76.6%)
Women = 214
(23.3%)
Total Patients 916/993
Clinical Presentation of Heart Failure
Chronic Compensated
Heart Failure > 3 months
FC 1 – 11
543 ( 59.2% )
Evaluated and managed in out
patient ( Heart failure / Screening
clinic )
Acute Decompensation of
Chronic Heart Failure (ADCHF)
+ Advanced HF syndromes
210 ( 22.9 % )
FC 111,1V
Seen while In patient / at early
post discharge HF clinic .
Acute De-Novo Heart
failure FC 11 to 1V
With in 3 months of
HF symptoms
163 ( 17.7 %)
With mild to moderate
symptoms evaluated at
RAHFC/ Screening clinic
9. MHFR
Heart Failure Death Audit
“Those who did not die by sword,
Died any how.
Causes of death are many
But the result is one.”
Iben alsaadi Baghdad Iraq 941
10. MHFR Makkah Heart Failure Registry
“HF Death Audit “
Men = 71/993
( 78.8%)
Women = 19/993
( 21.1%)
Total Patients 90/993
( 9.0% )
Men death average age
60.1 years
Women death average age
63.8 years
Over all death average age =
60.9 years
Age classification Total deaths = 90 Men Deaths =71 ( 78.8 ) Women = 19 ( 21.1 % )
18 to 45 years 11 ( 12.2% ) 9 2
46 to 65 years 50 ( 55.5% ) 40 10
> 65 years 29 ( 32.2% ) 22 7
Group I 23 /330 ( 6.9% ) 18 to 45 Years 5 ( M , 4 F , 1 ) 46 to 65 Years 13 ( M ,11 F , 2 > 65 Years 5 ( M 3 , F 2 )
Group II 52 /586 ( 8.8% ) 6 ( M , 5 F , 1 ) 27 ( M, 22 F , 5 19 ( M ,15 F ,4
Group III 15/77 ( 19.4% ) 000000 10 ( M , 7 F , 3 5 ( M , 4 F , 1
Men death 71 /752
( 9.4 % )
Women death
19/241
( 7.8 % )
11. MHFR ( Makkah Heart Failue Registry)
Saudi Heart association Virtual conference 7th October 2021.
Patients Demoghraphy and clinical characteristics
KAMC Classification of Ischemic HF Syndromes. 428/993 ( 43% )
HF Groups
I - III
Type I
72 ( 17%)
( HF with Acute MI)
Type II
162 ( 37.8%)
( HF with old MI )
Type III
17 ( 4%)
( HF with Angina, no MI )
Type IV
101 ( 24% )
( Primary HF ,no MI,no
angina )
Type V
76 ( 18%)
( HF with Old CABG )
Group I
128/330
( 38.7%)
04 ( 3.1% ) 63 ( 49.2% 3 ( 2.3% ) 31 ( 24.2%) 27 ( 21%)
Group II
250/586
( 42.6% )
31 ( 12.4%) 96 ( 38.4% 12 ( 4.8%) 65 ( 26.%) 46 (18.4%)
Group III
50/77 (64.9%)
37 (74%)
28 STEMI
9 NSTEMI
03 ( 06%) 02 (0 4%) 05 ( 10%) 03 ( 06%)
12. MHFR ( Makkah Heart Failure Registry)
Saudi Heart association conference 7th October 2021.
Patients Demoghraphy and clinical characteristics
KAMC Classification of Non Ischemic HF Syndromes. 565/993 ( 56.8% )
HF Groups
I - III
Idiopathic
210/565
( 37.1%)
Valvular
125/565
( 22.1%)
Captagon
DCM
56/565
(9.9%)
Chemotherapy
DCM
35/565
( 6.1% )
Miscellanous
139/565
( 24.6%)
Group I
202/330
( 61.2%)
99/ 202
( 49.0% )
15/202
( 7.4%
33/202
( 16.3% )
11/202
( 5.4%)
44/202
( 21.7%)
Group II
336/586
( 57.3% )
111/336
( 33.%)
95/336
( 28.2%
23/336
( 6.8%)
24/336
( 7.1 %)
83/336
(24.7%)
Group III
27/77 (35.0%)
None 15/27
( 55%)
None None 12/27
( 44.4%)
13. KAMC Heart Failure Registry
“An Sacubitril Audit “
Captagon
Strangely most patients did not know cardiovascular adverse effects of captagon, Bit neglected population, from families, single
/divorced, even neglected by physicians for advanced therapies. They used drug for different reasons, long route drivers during
Hajj and Ramdan umrah, Sex drive, some just want to be awake, etc. It cause excessive thrombo emboloism, LV thrombus,
stroke, pulm embolism,systemic emboli ,coronary spasm, Severe mostly irreversible systolic dysfunction ,valve regurgitation.
Captagon ( Amphetamine) Induced Cardiomyopathy with severe LV systolic
Dysfunction.( Mainly Captagon + Alcohol & Hashish )
Total No of Captagoninduced HF Patients on Sacubitril = 33/330 ( 10% )All Men
Age Range 19 years to 63 years
Average Age 43 years
Severe LV systolic Dysfunction
Ejection Fraction EF < 25% = 78.9%
EF > 25% < 35% 21%
Etiologically
26 ( 78.7% ) Dilated Cardiomyopathy
7 ( 21.2% ) Ischemic with Old MI ( coronary spasm) .
Ischemic type 1V without MI and no angina.
Please do not ignore
them. They are equally
responsive to
treatment
Majority Patients
Tolerate ( GDMT)
Sacubitril 200mg
bid
14. MHFR ( Makkah Heart Failure Registry)
Saudi Heart Association Virtual Conference 7th October 2021
Patients Demoghraphy and clinical characteristics
Echocardiogram & LV Ejection fraction ( Done in 98% )
MHFR
Average LVEF 29+_ 12.3%
LVEF < 40% LVEF > 40 to 50 > 50% No Echo
330/330
100%
Excluded Excluded Excluded
401 / 586
68%
( 17 Patients
EF 35-40% )
58 /586
9.8%
108/586
18.4%
19/586
3.2%
53/77
68.8%
10/77
12.9%
14/77
18.1%
************
784/993
78.9%
Group I
330 Patients on ARNI
Average EF 23.2+_ 7.4%
Group II
586 Patients without ARNI
Average EF 31.7+_ 13.4%
Group III
77 Patients Hajj 2019
Average EF 33.8 +_ 0.4%
Total Patients
993
248 / 330 75% EF < 25%
384/586 65.5% EF < 35%
In 78.9% Patients LVEF was < 40%
15. MHFR Results
Registry includes 993patients; average age 56.9 ±13.2 year; 75.8% were
males; average LVEF of 29 ±12.3%. Aetiologically : 43.1 % ischemic, 35%
dilated, and 21.8 % miscellaneous.
4.9% had ICD and 5.2% had CRTD implantation .
Group I , comprise 330 patients (33.1%) were treated with
Sacubitril/valsartan. Average age 53.9 ±12.3 year; 83.5% males; average LVEF
of 23.2 ±7.4%. Aetiology: 128 ( 38.7% ) ischemic, 202 ( 61.2 % ) were non
ischemic. 172 (52.1%) reached target dose of 200 within 4.2±2.7 months.
Group II , comprise 586 patients (59%) were treated with optimal medical
treatment, average age 57.7 ±13.5 year; 72.2% are males; average LVEF of 31.7
±13.4%. Aetiology: 250 ( 42.6% ) were ischemic, 299 ( 51.0% ) were non
ischemic 37 ( 6.3 % ) were miscellaneous with out Coronary angiogram .
Group III , 77 patients (7.8%) were Hajji in 2019, average age 63.8 ±10.8 year;
64.9% males; average LVEF of 33.8 ±0.4%. Aetiology: 50 ( 64.9% ) ischemic, 27
( 35% ) non ischemic ( 15 55.5 % Valvular , and 12 ( 44.4% ) miscellaneous.
16. MHFR ( Makkah Heart Failure Registry)
Saudi Heart Association Conference 7th October 2021
Total Patients 993 Average Age 56.9 + _ 13.2 years ( Men 752 ( 75.7% ) Women 241( 24%
Patients Demoghraphy and clinical characteristics
Registry groups &
No of Patients
Location of registry
Type of Registry
Average Age
Men/ Women %
Ischemic Etiology
Valvular Etiology
On Target Dose
Of Sacubitril
Average LVEF %
HF in Saudis
Deaths = 90
Group I = 330 ( 33.2% ) Group II = 586 ( 59% ) Group III = 77 ( 7.7% )
Acute & chronic HF KAMC Cardiac
Center ( October 2018 to june 21)
Acute & Chronic HF KAMC Cardiac
Center ( October 2018 to June 21 )
Acute HF KAMC Cardiac Center
30 Days ,August Hajj 2019
Sacubitril Registry EF < 40% Non Sacubitril Registry
Both systolic and Perserved EF
Non Sacubitril Registry
Both Systolic & Perserved EF
53.9 +_ 12.3 Years 57.7 + _ 13.5 Years 63.8 + _ 10.8 Years
Men 278 ( 83.5 % ) Women 52 ( 15.7% ) Men 424 (72.2 % ) Women 162 ( 27.6%) Men 50( 64.9 % ) Women 27 ( 35% )
128/330 ( 38.7% ) 250/586 ( 42.6% ) 50/77 ( 64.9% )
15/202 non ischemic ( 7.4% ) 95/ 314 ( Non ischemic ) 30.2% 15/27 ( Non ischemic ) 55.5%
172/ 330 ( 52.1% ) Not Prescribed Not Prescribed
23.2 + _ 7.4% 31.7 + _ 10.8 % 33.8 + _ 0.4%
290/330 ( 87.8% ) 524/685 ( 89.4% ) 2/77 ( 2.5 % )
23 /330 ( 6.9% ) M = 18, F = 5 52/586 ( 8.8 % ) M = 42 F = 10 15/77 ( 19.4% ) M = 11, F = 4
17. Summary & Recommendations
Heart failure is common & complex public health
problem all over, and in Holy Makkah indeed.
KAMC being advanced Heart failure center has
honor to establish ( MHFR ) Makkah Heart
Failure registry of 993 HF patients during October
2018 to June 2021.
Looking at the magnitude of HF in Makkah region,
weekly tiny heart function clinic for regular HF
patients is not sufficient to improve heart failure
services for people of Makkah.
18. Summary& Recommendations
Currently heart failure services are fragmented .
To overcome problem, we need to establish a state of art
multidisciplinary heart failure program and HF network indeed (
Grade 1 to 111 Community HF and advanced HF services in
existing Makkah health care cluster )
Our patients are 10 to 15 years younger than western HF
population, HF problems will further grow because of
awareness and advancement in revascularization , CHD
correction in childhood, Valve surgery and expansion of
advance therapies ( CRTD,ICD LVAD& Valve implants) .
19. Summary & Recommendations
Heart Failure ist admission and readmission are two different
syndromes.
77% of HF expenditure is on hospitalization, to
overcome complex situation there is a dire need to
implement model of multidisciplinary HF project .
We need to have HF services under one umbrella ( out
patient, Inpatient, Emergency HF and Community HF
services) .
Establishment of Regular rapid Access HF clinic
( RAHFC ) ,post discharge HF clinic ( PDHFC) , Nurse led HF clinic
and last not the least very complex advanced heart failure
clinic indeed .
20. Summary & recommendations
This game changer revolutionary heart failure
medication of the current century ( ARNI ),
must be used at least in centers with availability of
Heart function clinic ,if not heart failure program
indeed.
GDMT & recommended dose titration must be tried
before consideration of expensive device therapies
( ICD,CRTD,LVAD and MV Clip).
ARNI monitoring through out HF journey
( even low dose ) and dose titration to 200 mg is
cornerstone to achieve good outcomes.
21. MHFR ( Makkah Heart Failure Registry )
Saudi Heart Association conference 7th October 2021
Patients Demoghraphy and clinical characteristics
Referrences 1 Terzic A, Waldman S. Chronic diseases: the emerging
pandemic. Clin Transl Sci 2011;4(3):225e6.
[2] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11): e442.
[3] Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and
middle-income countries. Lancet 2007;370(9603):1929e38.
[4] Guy GW, Nunn AVW, Thomas LE, Bell JD. Obesity, diabetes, and longevity in the Gulf: is there a Gulf metabolic syndrome? JDM
2009;1:43e54.
[5] Bassiony MM. Smoking in Saudi Arabia. Saudi Med J 2009; 30(7):876e81.
[6] Najafi F, Jamrozik K, Dobson AJ. Understanding the ‘epidemic of heart failure’: a systematic review of trends in
determinants of heart failure. Eur J Heart Fail 2009;11:472e9.
[7] Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J
2010;31:784e93.
[8] Gheorghiade M, Braunwald E. Hospitalizations for heart failure in the United States-a sign of hope. JAMA 2011;6:705e6.
[9] Agarwal AK, Venugopalan P, de Bono D. Prevalence and aetiology of heart failure in an Arab population. Eur J Heart Fail
2001;3:301.
[10] AlHabib KF, Hersi A, AlFaleh H, Kurdi M, Arafah M, Youssef M, et al. The Saudi project for assessment of coronary
events (SPACE) registry: design and results of a phase I pilot study. Can J Cardiol 2009;25:e255e8.